To examine whether EGFR hyperactivation could serve as a target for anti-cancer interventions in HCC, liver cancer cell line data from DepMap was used to correlate Reverse Phase Protein Array (RPPA) measurement of EGFR_Y1068, a site that is crucial to EGF-induced Ras/MAPK signaling (49), with response to afatinib, an EGFR-specific tyrosine kinase inhibitor. The gene discussed is EGFR; the disease is hepatocellular carcinoma.